FDA Approves Lilly Treatment
Lilly says more than 246
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowThe U.S. Food and Drug Administration has approved a new treatment by Indianapolis-based Eli Lilly and Co. (NYSE: LLY). The injectable Taltz is used to treat adults with moderate-to-severe plaque psoriasis.
The FDA says psoriasis is a skin condition that causes patches of skin redness and flaking. Lilly says it affects as many as 7.5 million Americans, about 20 percent of whom have moderate-to-severe psoriasis.
"Many people living with plaque psoriasis are looking for another treatment option for this disease," said Alex Azar, president of Lilly USA LLC. "With this FDA approval, we are proud to provide patients and dermatologists with a new choice that may provide significant improvement of psoriasis plaques."
The FDA says Taltz is administered as an injection. In a news release, the agency said, "it is intended for patients who are candidates for systemic therapy (treatment using substances that travel through the bloodstream, after being taken by mouth or injected), phototherapy (ultraviolet light treatment) or a combination of both."
"Today’s approval provides patients suffering from plaque psoriasis with another important treatment option to help relieve the skin irritation and discomfort from the condition," said Julie Beitz, director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research.